Home » Newsletters » BioWorld

BioWorld

June 17, 2003

View Archived Issues

Celltech, BMS Stop Development Of NSCLC Product After Phase II

Arizona Scientists Probe Pros, Cons Of Aspirin Mixed With Other Items To Avoid Recurrence Of Malignancy

Deltagen Considers Bankruptcy; Lease Deal Ending, Officers Quit

Correction

Cytogen Regains Rights To Berlex's Cancer Pain Product

Other News To Note

ICOS Planning To Raise $250M Through Private Sale Of Notes

ICOS Corp. is looking to raise $250 million through an offering of convertible subordinated notes. (BioWorld Today) Read More

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...